AstraZeneca acquires Alexion Pharmaceuticals for $39 billion, or $175 per share. Alexion shareholders will receive $60 and 2.1243 ADRs of AstraZeneca for each of their shares. As a result, they will own 15% of the combined company. The transaction is expected to close in Q3 2021, subject to shareholder approval from both companies.